Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients.

Published

Journal Article

OBJECTIVE: The coming obesity epidemic in elderly persons necessitates the establishment of new and easy-to-use cardiometabolic markers to identify individuals most likely to develop atherosclerosis among hypertensives. METHODS: We measured plasma HMW adiponectin and des-acyl ghrelin levels, and carotid-artery intima-media thickness (cIMT) in 263 elderly hypertensives (mean 72.6 years; 37%men). Other cardiometabolic markers, including metabolites, inflammation, and hemostasis, were also measured. RESULTS AND CONCLUSION: Both HMW adiponectin and des-acyl ghrelin levels were inversely correlated with obesity. The HMW adiponectin level was favorably associated with glucose and lipid metabolites, PAI-1 (all P<0.05), and hs-CRP (P=0.07) after adjustment for age, sex, and BMI; however, it had no correlations with cIMT. In contrast, although there were no correlations between des-acyl ghrelin and cardiometabolic markers, except for a positive association with the nitrite/nitrate (NO(x)) level (P=0.002), des-acyl ghrelin had a significant inverse correlation with cIMT (P=0.003). A multivariable regression analysis showed that des-acyl ghrelin, but not HMW adiponectin, was significantly associated with cIMT after adjusting for age, obesity, sex, smoking, 24-h BP, and other cardiometabolic factors (beta=-0.178, P=0.001). Moreover, the increased risk of cIMT among those with abdominal obesity compared with non-obesity (0.833+/-0.185 mm vs. 0.782+/-0.163 mm, P=0.019) was explained by the elevated 24-h BP and reduced des-acyl ghrelin level, but not by other cardiometabolic parameters. These associations were unchanged after adding NO(x) to the model. In conclusion, the des-acyl ghrelin level is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensives, and the pathologic pathway linking these factors is independent of its NO bioactivity.

Full Text

Duke Authors

Cited Authors

  • Yano, Y; Toshinai, K; Inokuchi, T; Kangawa, K; Shimada, K; Kario, K; Nakazato, M

Published Date

  • June 2009

Published In

Volume / Issue

  • 204 / 2

Start / End Page

  • 590 - 594

PubMed ID

  • 19041092

Pubmed Central ID

  • 19041092

Electronic International Standard Serial Number (EISSN)

  • 1879-1484

Digital Object Identifier (DOI)

  • 10.1016/j.atherosclerosis.2008.10.013

Language

  • eng

Conference Location

  • Ireland